viewAnteris Technologies Ltd

Admedus successfully implants second patient in SAVR trial

The company is focused on bringing DurAVR™ to market, building on the company’s cardiovascular patches using its ADAPT® tissue technology.

Admedus Ltd - Admedus successfully implants second patient in SAVR trial
The 3D single-piece aortic valve has the potential to transform heart surgery

Admedus Ltd (ASX:AHZ) has successfully implanted an ADAPT® treated DurAVR™ 3D single-piece aortic valve in a second patient at the University Hospitals Leuven, Belgium, in its first-in-human surgical aortic valve replacement (SAVR) study.

The first patient was implanted in April and Admedus chief executive officer Wayne Paterson said both patients were recovering well.

He said: “The first patient, implanted with DurAVR™ 3D single-piece aortic valve on March 26, 2020, is doing well, over a month post-implantation and patient two is recovering as expected.

“Given the challenges that the COVID-19 pandemic is presenting for hospitals, it is encouraging to see the second surgery completed.

“We are grateful to the surgeon and the patient for undergoing the procedure.”

Fifteen patients are to be enrolled in the study and followed up for six months after implantation.

Unique tissue technology

In heart surgery, one of the biggest issues facing patients – and surgeons – is finding a replacement valve that will last the life of the patient.

The current commercial devices start failing as early as five years after the procedure.

Admedus’ ADAPT® tissue technology, invented by Perth professor Leon Neethling, has been taken from discovery to global commercialisation and has proven to be the only tissue to last beyond 10 years in the human body.

With 62 million people globally suffering from aortic stenosis – a condition that narrows the valve and in severe cases requires a repair or replacement procedure - this is a major market for Admedus.

Shares today have been up as much as 12 cents to $7.65 intra-day.

Quick facts: Anteris Technologies Ltd

Price: 5.2 AUD

Market: ASX
Market Cap: $32.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read